Literature DB >> 15297502

Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest.

Aristea Velegraki1, Evangelos C Alexopoulos, Stavroula Kritikou, George Gaitanis.   

Abstract

A novel formulation of RPMI 1640 medium for susceptibility testing of Malassezia yeasts by broth microdilution (BMD) and Etest is proposed. A modification of the NCCLS M27-A2 BMD method was used to test 53 isolates of Malassezia furfur (12 isolates), M. sympodialis (8 isolates), M. slooffiae (4 isolates), M. globosa (22 isolates), M. obtusa (2 isolates), M. restricta (2 isolates), M. pachydermatis (1 isolates), and M. dermatis (2 isolates) against amphotericin B, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, and posaconazole by BMD and Etest. RPMI and antibiotic medium 3 (AM3) were supplemented with glucose, bile salts, a mixture of fatty acids, and n-octadecanoate fatty acids and Tween 20. M. furfur ATCC 14521 and M. globosa ATCC 96807 were used as quality control strains. Depending on the species, MICs were read after 48 or 72 h of incubation at 32 degrees C. Low azole and terbinafine MICs were recorded for all Malassezia species, whereas amphotericin B displayed higher MICs (>/=16 microg/ml) against M. furfur, M. restricta, M. globosa, and M. slooffiae strains, which were AM3 confirmed. Agreement of the two methods was 84 to 97%, and intraclass correlation coefficients were statistically significant (P < 0.001). Because of higher amphotericin B MICs provided by Etest for strains also displaying high BMD MICs (>/=1 microg/ml), agreement was poorer. The proposed media are used for the first time and can support optimum growth of eight Malassezia species for recording concordant BMD and Etest MICs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297502      PMCID: PMC497592          DOI: 10.1128/JCM.42.8.3589-3593.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Susceptibility testing of Malassezia species using the urea broth microdilution method.

Authors:  Y Nakamura; R Kano; T Murai; S Watanabe; A Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Systemic infection with Malassezia furfur in an adult receiving long-term hyperalimentation therapy.

Authors:  R Brooks; L Brown
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

3.  Improved methods for isolation and enumeration of Malassezia furfur from human skin.

Authors:  J P Leeming; F H Notman
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

4.  In vitro activity of systemic antifungal agents against Malassezia furfur.

Authors:  M J Marcon; D E Durrell; D A Powell; W J Buesching
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine.

Authors:  A K Gupta; Y Kohli; A Li; J Faergemann; R C Summerbell
Journal:  Br J Dermatol       Date:  2000-04       Impact factor: 9.302

6.  Intracardiac mass complicating Malassezia furfur fungemia.

Authors:  K A Schleman; G Tullis; R Blum
Journal:  Chest       Date:  2000-12       Impact factor: 9.410

7.  Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Houston; K Mills; A Bolmstrom; R N Jones
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

8.  Systemic Malassezia furfur infections in patients receiving intralipid therapy.

Authors:  R W Redline; S S Redline; B Boxerbaum; B B Dahms
Journal:  Hum Pathol       Date:  1985-08       Impact factor: 3.466

9.  Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Karlsson; A Bolmström
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Description of a new yeast species, Malassezia japonica, and its detection in patients with atopic dermatitis and healthy subjects.

Authors:  Takashi Sugita; Masako Takashima; Minako Kodama; Ryoji Tsuboi; Akemi Nishikawa
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

View more
  22 in total

1.  In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains.

Authors:  Christine Roques; Sabine Brousse; Cédric Panizzutti
Journal:  Mycopathologia       Date:  2006-12       Impact factor: 2.574

2.  In vitro amphotericin B susceptibility of Malassezia pachydermatis determined by the CLSI broth microdilution method and Etest using lipid-enriched media.

Authors:  Sergio Álvarez-Pérez; José L Blanco; Teresa Peláez; Maite Cutuli; Marta E García
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Strain-Specific Metabolic Requirements Revealed by a Defined Minimal Medium for Systems Analyses of Staphylococcus aureus.

Authors:  Henrique Machado; Liam L Weng; Nicholas Dillon; Yara Seif; Michelle Holland; Jonathan E Pekar; Jonathan M Monk; Victor Nizet; Bernhard O Palsson; Adam M Feist
Journal:  Appl Environ Microbiol       Date:  2019-10-16       Impact factor: 4.792

4.  Prolonged fever and splenic lesions caused by Malassezia restricta in an immunocompromised patient.

Authors:  Annabelle de St Maurice; Haydar Frangoul; Alice Coogan; John V Williams
Journal:  Pediatr Transplant       Date:  2014-09-03

5.  In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.

Authors:  Mamiko Miyazaki; Takaaki Horii; Katsura Hata; Nao-Aki Watanabe; Kazutaka Nakamoto; Keigo Tanaka; Syuji Shirotori; Norio Murai; Satoshi Inoue; Masayuki Matsukura; Shinya Abe; Kentaro Yoshimatsu; Makoto Asada
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

6.  A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.

Authors:  S Rincón; M C Cepero de García; A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 7.  The Malassezia genus in skin and systemic diseases.

Authors:  Georgios Gaitanis; Prokopios Magiatis; Markus Hantschke; Ioannis D Bassukas; Aristea Velegraki
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

8.  Antifungal Susceptibility Testing of Malassezia spp. with an Optimized Colorimetric Broth Microdilution Method.

Authors:  Cheryl Leong; Antonino Buttafuoco; Martin Glatz; Philipp P Bosshard
Journal:  J Clin Microbiol       Date:  2017-04-05       Impact factor: 5.948

9.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.

Authors:  Junichi Mitsuyama; Nobuhiko Nomura; Kyoko Hashimoto; Eio Yamada; Hiroshi Nishikawa; Makoto Kaeriyama; Akiko Kimura; Yozo Todo; Hirokazu Narita
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

10.  CLSI broth microdilution method for testing susceptibility of Malassezia pachydermatis to thiabendazole.

Authors:  Patrícia da Silva Nascente; Ana Raquel Mano Meinerz; Renata Osório de Faria; Luiz Filipe Damé Schuch; Mário Carlos Araújo Meireles; João Roberto Braga de Mello
Journal:  Braz J Microbiol       Date:  2009-06-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.